Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Twist Bioscience

Twist Bioscience

Twist Bioscience is a DNA synthesis company using a next-generation silicon-based technology platform.

All edits

Edits on 21 Sep, 2022
Александр Янукович"Edit from table cell"
Edits made to:
Infobox (+1 properties)
Infobox
Glassdoor ID
Edits on 19 Sep, 2022
Katrina-Kay Pettitt"prospector:1906:1376614"
Katrina-Kay Pettitt edited on 19 Sep, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Edits on 5 Sep, 2022
Artemii CHernyshev"Edit from table cell"
Artemii CHernyshev edited on 5 Sep, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 30 Aug, 2022
Amy Sar
Amy Sar edited on 30 Aug, 2022
Edits made to:
Infobox (+3 properties)
Infobox
Industry
Edits on 16 Aug, 2022
Amy Tomlinson Gayle
Amy Tomlinson Gayle edited on 16 Aug, 2022
Edits made to:
Infobox (+1 properties)
Timeline (+14/-8 events) (+2098/-3585 characters)
Description (+21/-1 characters)
Article (+1189/-1095 characters)
Topic thumbnail

Twist Bioscience

ATwist Bioscience is a DNA synthesis company using a next-generation silicon-based technology platform.

Article
Overview

Twist Bioscience was founded in 2013 by Emily Leproust to commercialize a high-throughput semiconductor-based DNA synthesis technology. The company supplies DNA for research and commercial applications of genetic engineering, and is developing additional markets for applications including digital data storage and DNA origami-based biomaterials and nanostructures.

...

Twist Bioscience can achieve 1,000x improvements in DNA production density by scaling down from the traditional 96-well plate to tiny micro-wells and channels on a silicon chip of the same area. Throughput is greatly increased because semiconductor-based technology allows the chemical reactions necessary for DNA synthesis to be scaled down by a factor of 1,000,000. Twist Bioscience is able to produce 9,600 genes on a single silicon chip using theirits technology;, compared to 1 gene being produced on the same amount of space using traditional DNA synthesis technologies.

...

In the video below, the CEO of Twist Bioscience, Emily Leproust, explains the innovations in DNA synthesis technology.

...

Applications of Synthetic DNA
...

1Applications of Synthetic DNA

Application
Description

Chemical Production

ReduceReduces the cost of introducing new genes into microorganisms that produce chemicals

Crop Optimization

ImproveImproves the throughput and reducereduces the cost of genetically engineering crops

Drug Discovery

EnableEnables more rapid, cheaper protein engineering for drug discovery

Functional Genomics

LowerLowers the cost of identifying disease gene targets

Genome Editing

ReduceReduces the cost and increaseincreases the efficiency of CRISPR technology

...

NextClonal generationgenes are next-generation sequencing (NGS) verified gene clones with no type II S restriction sequences and custom vector onboarding with verification. There is currently a lower limit of 10+ten genes (no upper limit ) to place an order that will be ready within 20twenty business days.

1Clonal gene details

Product details
Information

Custom cloning

$50/construct

Minimum order

10 genes

Price

9¢/base

Size

0.3-3.2 kb

Turnaround time

20 business days

...

1Combinational libraries details

Product details
Information

Delivery and yield

Single tube, 1 ug total

Price

Project-dependent

Product format

Linear double-stranded DNA

Turnaround time

4-6 weeks, project dependent

...

DNA is being developed as a storage medium for digital data. Twist Bioscience is working with Microsoft and the University of Washington to improve data storage using DNA, and havehas published research demonstrating high-fidelity storage and random-access retrieval of over 200 MB of data, including an OK Go music video. As the technology matures, DNA could offer a high-density, low-energy, long-term, and secure digital data storage solution. Twist Bioscience explains their work on DNA data storage in their white paper.

...

Gene fragments are non-clonal, and can be used for several downstream cloning methods for assembly into bigger genes or pathways. The error rate on gene fragment production is approximately 1:3000 base pairs.

...

1Gene fragment details

Product details
Information

Max size

0.3-1.8kb

Minimum order

10 genes

Price

7¢/base

Turnaround time

7-10 business days

Yield

200ng/fragment

...

Oligo pools are made to be diverse collections of oligonucleotides and can be used for applications such as the creation of CRISPR sgRNA libraries high-throughput reporter essays. Oligo pools are madedesigned to be highly uniform and accurate for maximal oligo representation and have an error rate of approximately 1:1000 nucleotides (nt).

...

1Oligo pool information

Product details
Information

Minimum order

2,000

Oligo length

Up to 200 nt

Oligo pool size

2,000 to 1,000,000 oligos

Price

Quote

Turn around time

10 days

...

1Site saturation libraries details

Product details
Information

Delivery and yield

Single tube, 1-2ug total. 96 plate well, 1/2 positions per well of 50 ng each. 384 well plate, 1/2 positions per well of 50 ng each.

Minimum order

48 variants

Price

$50/position

Product format

Linear double-stranded DNA

Turnaround time

3-4 weeks, project dependent

...

The Twist human core exome kit is a DNA probe target enrichment kit. It comes with modular high performancehigh-performance DNA probes designed to uniformly and accurately capture sequence depth. The modular kit is simple to integrate into existing lab protocols due to its has many customization options.

...

The turnaround time for orders is still relatively long compared to other lab-based methods, especially for smaller amounts of DNA. Therefore, in certain instances, it is more reasonable for researchers and companies to utilize traditional cloning methods depending on the genes needed for experiments. Slow turnaround time for smaller orders is the primary reason Ginkgo Bioworks acquired Gen9, which brought that function in-house.

...

In 2016, Agilent filed a lawsuit against Twist Bioscience, alleging Emily Leproust, a former Agilent employee, stole trade secrets developed by the company to start the DNA synthesis startup.

...

On May 27th27, 2014, Twist Bioscience received $5.1 million dollars in funding from the Defense Advanced Research Defense Advanced Research projectsProjects Agency Agency (DARPA). The contract was awarded to Twist Bioscience under DARPA's Living Foundries program.

...

On Feb 10, 2014, Twist Bioscience received $9,100,000 in series A funding from Asset Management Ventures (AMV).

...

On May 27, 2014, Twist Bioscience completed a $26,000,000 series B funding round. Investors include:included DARPA, ARCH Venture Partners, Paladin Capital GroupPaladin Capital Group, Yuri MilnerYuri Milner, and some undisclosed investors.

...

On June 10, 2015, Twist Bioscience closed a $37,000,000 series C funding round. Investors include: Foresite CapitalForesite Capital, ARCH Venture PartnersARCH Venture Partners, Paladin Capital Group Paladin Capital Group, Venture Investors, Fidelity Management & ResearchFidelity Management & Research, Illumina, Joby PritzkerJoby Pritzker, and Yuri MilnerYuri Milner.

...

On March 27th27, 2017, Twist Bioscience closed a $61,000,000 series D funding round. Investors include: Foresite CapitalForesite Capital, ARCH Venture PartnersARCH Venture Partners, Paladin Capital GroupPaladin Capital Group, Fidelity Management & ResearchFidelity Management & Research, Illumina, Boris NikolicBoris Nikolic, Cormorant Asset Management, WuXi Healthcare Ventures, Yuri Milner,Yuri Milner, Mérieux Développement Mérieux Développement, ARCH Overage Fund, Nick Pritzker, and Joby Pritzker.

...

On June 14th14, 2017, Twist Bioscience closed a $27,000,000 series E funding round. Investors include:included Biomatics CapitalBiomatics Capital, Reinet Fund S.C.AReinet Fund S.C.A, F.I.S, NFT Investment Limited, KangMei Group, Bay City Capital, GF Xinde Life Science Investment Fund, 3W Partners Capital, and Ditch Plains Capital ManagementDitch Plains Capital Management LP.

...

On April 3rd3, 2018, Twist Bioscience received $50,000,000 in funding from private investors.

...

In June 2016, Twist Bioscience became partners with Desktop Genetics, a company using AI to create CRISPR screens. The partnership focuses on developing and integrating DNA synthesis tools to design research protocols that enhance gene editing research. Desktop Genetics works with theirits customers to design CRISPR sgRNA libraries for a cell line before sending this information to Twist Bioscience for sgRNA library synthesis. This partnership aims to reduce the cost and improve the efficiency of gene editing research.

...

In June 2017, the BioBricks foundation partnered up with Twist Bioscience on the Free Genes project, an initiative to create an open-source library of 10,000 genes that form biological parts important for synthetic biology. Twist Bioscience will be providing all the DNA that will be used for the project, and BioBricks will assemble a library of useful genes using its team and drawing on support from the scientific community. All genetic constructs created through this partnership will be made freely available to the public through the Open Material Transfer Agreement, which allows any recipient to use, modify, combine, copy, and redistribute the genes (in compliance with applicable biosafety and intellectual property laws).

...

In July 2017, Quintara Bioscience and Twist Bioscience became business partners, announcing theyit willwould be working together to create qBlock Gene Fragment and qGene DNA cloning services. Twist Bioscience will combinecombines theirits silicon DNA synthesis technology with Quintara Bioscience's sequencing and cloning technologies to deliver gene fragment and cloning services.

...

Twist Bioscience and Synbio Technologies became partners on July 11th11, 2017. The partnership seeks to combine technologies being used at both companies, by offering DNA strands up to 70 kilobases in length. Twist Bioscience will synthesize DNA strands up to 3.2 kilobases in length before shipping them off to Synbio Technologies for completion. This partnership gives both companies more international presence: Twist Bioscience inis located in San Francisco, and Synbio Technologies is in China, so by working together, they plan to be able to offer improved DNA strand products that enhance scientific research for the diagnosis and treatment of disease.

...

On April 6th, 2016, Twist Bioscience acquired the Israeli software company Genome Compiler for an undisclosed price. Twist plans to use Genome Compiler's software developers and technology to build an an e-commerce platform that allows customers to create their own gene designs online before ordering, and to leverage theirits strong software development team for future projects.

...

According to BCC Research, the overall market for synthetic biology products iswas expected to grow from $4.4 billion in 2017 to over $13.9 billion by 2022.

Twist serves 600 customers across the three areas of the synthetic biology market in a broad range of industries. Revenue was $20.5 million for the trailing 12 months ended June 30, 2018, and revenue in the quarter ended Sept. 30, 2018, the company's fiscal year end, is estimated to be between $8.0 million and $8.3 million. Ginkgo Bioworks is Twist Bioscience's largest customer, accounting for 32% of revenue.

...

Twist serves 600 customers across the three areas of the synthetic biology market in a broad range of industries. Revenue was $20.5 million for the trailing twelve months ended June 30, 2018, and revenue in the quarter ended Sept. 30, 2018, the company's fiscal year-end, is estimated to be between $8.0 million and $8.3 million. Ginkgo Bioworks is Twist Bioscience's largest customer, accounting for 32% of revenue.

Infobox
Timeline

August 16, 2022

Twist's COVID-19 test, which can detect variants, gets authorized.

August 16, 2022

Twist Bioscience launches monkeypox virus synthetic DNA controls.

August 16, 2022

Twist Bioscience inks an antibody discovery pact with MediSix Therapeutics.

August 16, 2022

Twist Bioscience and Ginkgo Bioworks sign a new Collaboration.

August 16, 2022

Twist Bioscience Q3 sales jump 60 percent and raises FY22 revenue outlook surpassing consensus.

August 16, 2022

Centogene and Twist Bioscience team up to develop rare disease tests.

April 4, 2018

Private Placement Funding

On April 3rd, 2018 Twist Bioscience received $50,000,000 in funding from private investors.

April 4, 2018

Twist Bioscience receives $50,000,000 in funding from private investors.

July 11, 2017

Synbio Technologies Partnership

​Twist Bioscience and Synbio Technologies became partners on July 11th, 2017. The partnership seeks to combine technologies being used at both companies, by offering DNA strands up to 70 kilobases in length. Twist Bioscience will synthesis DNA strands up to 3.2 kilobases in length before shipping them off to Synbio Technologies for completion. This partnership gives both companies more international presence, Twist Bioscience in located in France, and Synbio Technologies is in China, and by working together they are able to offer improved DNA strand products that enhance scientific research for the diagnosis and treatment of disease.

July 11, 2017

Twist Bioscience and Synbio Technologies become partners as they seek to combine technologies being used at both companies, by offering DNA strands up to 70 kilobases in length.

July 11, 2017

Quintara Biosciences partners with Twist Bioscience to launch new gene fragment and cloning services, qBlocks, and qGenes.

July 1, 2017

Quintara Biosciences Partnership

In July 2017, Quintara Bioscience and Twist Bioscience became business partners, announcing they will be working together to create qBlock Gene Fragment and qGene DNA cloning services. Twist Bioscience will combine their silicon DNA synthesis technology with Quintara Bioscience's sequencing and cloning technologies to deliver gene fragment and cloning services.

June 15, 2017

Series E Funding Round

June 14th, 2017 Twist Bioscience received $27,000,000 after completing their series E funding round. Investors include: Biomatics Capital, Reinet Fund S.C.A, F.I.S, NFT Investment Limited, KangMei Group, Bay City Capital GF Xinde Life Science Investment Fund, 3W Partners Capital, and Ditch Plains Capital Management LP.

June 15, 2017

Twist Bioscience receives $27,000,000 after completing its series E funding round. Investors include Biomatics Capital, Reinet Fund S.C.A, F.I.S, NFT Investment Limited, KangMei Group, Bay City Capital GF Xinde Life Science Investment Fund, 3W Partners Capital, and Ditch Plains Capital Management LP.

June 1, 2017

Biobricks Foundation Partnership

In June 2017, the BioBricks foundation partnered up with Twist Bioscience to create a library of 10,000 genes that form biological parts important for synthetic biology. Twist Bioscience will be providing all the DNA that will be used for the project, and BioBricks will assemble a library of useful genes using its team and drawing on support from the scientific community. Everything created through this partnership is based on a Open Material Transfer Agreement that allows anyone to have free access to the genes.

June 1, 2017

Biobricks partners with Twist Bioscience to create a library of 10,000 genes that form biological parts important for synthetic biology.

April 28, 2017

Series D Funding Round
Twist Bioscience receives a $61,000,000 in a series D funding round.

​On March 27th, 2017 Twist Bioscience received $61,000,000 after completing their series D funding round. Investors include: Foresite Capital. ARCH Venture Partners, Paladin Capital Group, Fidelity Management & Research, Fidelity Management and Research Company, Illumina, Boris Nikolic, Cormorant Asset Management, WuXi Healthcare Ventures, Fidelity Management, Yuri Milner, Merieux Developpement, ARCH Overage Fund, Foresite Capital Management, WuXi, Corporate Venture Fund, Nick Pritzker, and Joby Pritzker.

June 1, 2016

Desktop Genetics Partnership

​In June, 2016 Twist Bioscience became partners with Desktop Genetics — a company using AI to create CRISPR screens. The partnership focuses on developing and integrating DNA synthesis tools and to design to design research protocols that enhance gene editing research. Desktop genetics works with their customers to predict sgRNA CRISPR libraries for a cell line before sending this information to Twist Bioscience for sgRNA library synthesis. This partnership claims to aim to reduce cost and improve efficiency of gene editing research.

June 1, 2016

Twist Bioscience partners with Desktop Genetics —a company using AI to create CRISPR screens.

The partnership focuses on developing and integrating DNA synthesis tools and to design research protocols that enhance gene editing research.

April 6, 2016

Acquisition of Genome Compiler
Twist Bioscience acquires Genome Compiler for an undisclosed price.

On April 6th, 2016 Twist Bioscience acquired the Israeli software company Genome Compiler for an undisclosed price. Genome Compilers software developers and technology will allow Twist Bioscience to build an an ecommercee-commerce platform that allows customers to create their own gene designs online before ordering; and have a strong software development team for future projects.

April 11, 2015

Series C Funding Round
Twist Bioscience receives $37,000,000 after completing its series C funding round.

On June 10, 2015 Twist Bioscience received $37,000,000 after completing their series C funding round. Investors include: Foresite Capital, ARCH Venture Partners, Paladin Capital Group, Venture Investors, Fidelity Management & Research, Illumnia, Joby Pritzker, and Yuri Milner.

May 28, 2014

Series B Funding Round
Twist Bioscience receives a $26,000,000 after completing its series B funding round.

​On May 27, 2014 Twist Bioscience received $26,000,000 after completing their series B funding round. Investors include: DARPA, ARCH Venture Partners, Paladin Capital Group, Yuri Milner, and some undisclosed investors. ​investors.​

May 27, 2014

Government Grant From DARPA

On May 27th, 2014 twist Bioscience received $5.1 million dollars in funding from the Defense Advanced Research projects Agency (DARPA). The contract was awarded to Twist Bioscience under DARPA's Living Foundries program.

May 27, 2014

Twist Bioscience receives $5.1 million dollars in funding from the Defense Advanced Research projects Agency (DARPA). The contract was awarded to Twist Bioscience under DARPA's Living Foundries program.

April 11, 2014

Series A Funding Round

​On Feb 10, 2014 twist Bioscience received $9,100,000 in funding from Asset Management Ventures (AMV) .

April 11, 2014

Twist Bioscience receives $9,100,000 in funding from Asset Management Ventures (AMV).

September 18, 2013

Twist Bioscience is founded
Edits on 28 Jul, 2022
Alexander Baychikov
Alexander Baychikov edited on 28 Jul, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Number of employees
652
Edits on 27 Jul, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 27 Jul, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 27 Jul, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 27 Jul, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 27 Jul, 2022
Infobox
Company Operating Status
Active
Founded date
2013
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 27 Jul, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 27 Jul, 2022
Infobox
Edits on 16 Jul, 2022
Patrick Pum
Patrick Pum edited on 16 Jul, 2022
Edits made to:
Infobox (+7/-2 properties)
Infobox
DUNS Number
051575309
Funding rounds
CAGE code
6Z0F4
CIK number
IRS number
462,058,888
Place of incorporation
SIC code
2,836
Edits on 30 Jun, 2022
Golden AI"remove blacklisted domain URLs"
Golden AI edited on 30 Jun, 2022
Infobox
Wikidata ID
Edits on 24 Jun, 2022
Amy Sar"prospector:1662:1294238"
Amy Sar edited on 24 Jun, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 9 Jun, 2022
Duzenko Andrey
Duzenko Andrey edited on 9 Jun, 2022
Edits made to:
Infobox (+5/-1 properties)
Infobox
Company Operating Status
Active
Founded date
2013
Exchange
Stock symbol
TWST
Wikidata ID
Full address
#03-50 Galaxis Workloft 3 Fusionopolis Place Singapore, 138523
5600 Avenida Encinas, Suite 140D-2 Carlsbad, CA 92008
Guangzhou International Bio-Island #36 Huanyu Third Road Guanzhou Life Science Innovation Center North Tower, Second Floor, Room 203 Guangzhou, P.R.China 510000
Rothschild Blvd 3 Tel Aviv 6425322, Israel
Edits on 29 May, 2022
Bezmenov Serhii"Edit from table cell"
Bezmenov Serhii edited on 29 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Email address
customersupport@twistbioscience.com
Edits on 17 May, 2022
Katrina-Kay Pettitt"prospector:1525:750930"
Katrina-Kay Pettitt edited on 17 May, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 19 Apr, 2022
Golden AI"update inverses"
Golden AI edited on 19 Apr, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 8 Apr, 2022
Golden AI"Patent autocalculation"
Golden AI edited on 8 Apr, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Patents assigned (count)
32
Golden logo
By using this site, you agree to our Terms & Conditions.